Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 187,800 shares, an increase of 84.5% from the November 30th total of 101,800 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average trading volume of 6,130,000 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a research note on Tuesday, December 10th. StockNews.com assumed coverage on Aptose Biosciences in a research note on Monday. They issued a “hold” rating for the company.

Institutional Trading of Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp raised its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities & Exchange Commission. 26.62% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Stock Performance

APTO traded down $0.01 during trading on Friday, reaching $0.24. 2,424,998 shares of the company traded hands, compared to its average volume of 1,790,199. The company has a market cap of $14.50 million, a P/E ratio of -0.08 and a beta of 1.06. Aptose Biosciences has a 12-month low of $0.13 and a 12-month high of $2.68. The firm has a fifty day simple moving average of $0.29 and a 200 day simple moving average of $0.45.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.